Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 12, 2018

View Archived Issues

Psoriasis and plaques

Small-molecule inhibitor of urokinase plasminogen activator ameliorates multiple sclerosis in mice

Small-molecule hepcidin production inhibitor developed for treatment of anemia of chronic disease

Novel RORgammat inhibitors developed by Shionogi for treating Th17-mediated autoimmune diseases

Interaction partner identification finds Myc's friends, and vulnerabilities

Seal Rock Therapeutics announces preclinical data for SRT-015 in NASH

CRISPR Therapeutics and MaxCyte expand clinical and commercial license agreement into oncology

Shanghai Jiongshuo Pharmaceutical Technology identifies CDK9/cyclin T1 inhibitors

FDA grants accelerated approval to Keytruda for HCC previously treated with sorafenib

GlaxoSmithKline patents PI3K inhibitors

FDA approves Yupelri for maintenance treatment of COPD

FDA issues EUA for DPP Ebola Antigen System

Harpoon Therapeutics to use series C proceeds to support cancer immunotherapy pipeline

New phase III trial investigates emixustat in macular atrophy secondary to Stargardt disease

Retrotope begins phase II/III study of RT-001 in infantile neuroaxonal dystrophy

Phase I data on BBT-401 pave way for phase II ulcerative colitis study

Adjunctive LHW-090 safely lowers blood pressure in patients with resistant hypertension

Purinergic receptor mutations cause congenital neurogenic bladder

Mutations in DKGE cause C3 glomerulopathy

Combination of IDLV-SIV-Gag and IDLV-PGT121 results in prolonged virus control in vivo

SCaV11 immunogen selectively elicits CD8+ T cells but not CD4+ T cells targeting viral antigens

Genetic determinants of cortical thickness in Alzheimer's disease revealed

Activation of the cellular stress response protects cells from neurotoxicity in Parkinson's disease

Gilead presents first-in-human data for GS-9688 at The Liver Meeting

PACAP/PAC1 signaling protects retinal neurons from death in mice with multiple sclerosis

Sierra completes IND filing for phase I/II trial of SRA-141 in colorectal cancer

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
At AACR: Epigenetic fingerprints in metastases track tumor origin
BioWorld
When a tumor migrates and colonizes another tissue or organ, it can be identified as a metastasis, but its origin is not always clear. Now, a study based on...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...